Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupSarcomasDiseaseChondrosarcomaSubgroupIDH1-MutationICD10C41.9MeSHChondrosarcomaSequenceChemotherapyChemo-substanceDasatinibIvosidenibPazopanibChemo-substanceDasatinibIvosidenibPazopanibChemo-substanceDasatinibIvosidenibPazopanibChemo-substanceDasatinibIvosidenibPazopanibNo. Substances1 RadiotherapySupportive therapySupportive substanceSupportive substanceSupportive substanceSupportive substanceNo. SubstancesProtocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlArthalgiaBleedingCardiotoxicityDiarrheaDyspneaEdemaEmetogenicity (ASCO)HypertensionHyponatremiaIncrease AminotransferasesLeukopeniaLymphopeniaNeutropeniaPainPleural EffusionProteinuriaQTc Time ExtensionRenal FailureThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorChow W Schuetze SMTap WDDiseaseChondrosarkom, Grad 1-2, Chordom, ab 13 J., ECOG 0-2Chondrosarkom, lokal fortgeschritten oder metastasiert, IDH1 Mutation, ECOG 0-1Chrondrosarkom, lokal fortgeschritten, oder metastasiert, ECOG 0-2OriginDepartment of Medical Oncology and Therapeutics Research, City of Hope Medical Center, Duarte, CaliforniaMemorial Sloan Kettering Cancer Center, New York, NYUniversity of Michigan, Ann Arbor, MichiganProtocols in Revision 3 protocols foundProtocols under revision.Dasatinib 70, Chondrosarcoma (PID2507 V1.0)Ivosidenib 500, chondrosarcoma (PID2506 V1.0)Pazopanib 800, Chondrosarcoma (PID2511 V1.0)
